Archived explainer. For the current picture see today's MRNA page.
MODERNA INC (MRNA) is down -10.83% in the latest session. Our newswire has captured 4 stories on MRNA across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 45/100).
Moderna Inc (NASDAQ:MRNA) shares fell 10.83% to $68.27 in the session, marking a sharp decline driven by a combination of profit-taking and bearish analyst commentary. The stock has already seen significant gains in recent months, with a 48% rise in June and a 3% increase in May, setting the stage for a pullback. Analyst ratings and market sentiment have shifted in recent days, contributing to the steep drop.
According to Stocktwits News, MRNA is facing its worst week in 11 months as investors take profits and react to cautious Wall Street commentary. TipRanks reported that JPMorgan reaffirmed its Sell rating on Moderna, leading to a 12% drop in shares on Friday. Meanwhile, RBC Capital raised its price target on Moderna to $45 from $38 on July 7, 2026, according to Yahoo Finance, but the move was not enough to offset the broader selling pressure. Yahoo Finance also included the stock in a general market update, though no specific details were provided.
Over the last eight trading sessions, the stock has fallen 1.1% from $70.03 to $69.25. Unusual options activity in the last 36 hours shows five notable prints, with call premium totaling $2.7 million versus $15,000 in put premium. The largest single print was $1.2 million. AI sentiment across the four stories in the last 36 hours averaged 45/100, below the neutral benchmark of 50. Social chatter showed two posts in 24 hours and seven-day sentiment at 45/100. Insiders have sold $5.9 million worth of shares in the last 90 days, with no buys reported.
The stock is set to remain in the spotlight as coverage breadth and sentiment evolve. Investors should monitor any further analyst commentary and potential earnings developments in the near term.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
The pullback appears driven by a mix of profit-taking and cautious Wall Street comments after a whopping 48% rally in June and a smaller 3% rally in May.
Moderna, Inc. (NASDAQ:MRNA) is one of the 10 Best Performing American Stocks in June 2026. On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said […]
Shares in Moderna ($MRNA) tumbled by 12% on Friday afternoon after JPMorgan ($JPM) reaffirmed its Sell rating on the U.S. pharma and biotech company. The banking gi...
More on MRNA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier MRNA move explainers: 2026-07-17 · 2026-07-11